Medical Condition News

RSS

New way to accurately test for peanut allergy

Researchers from Murdoch Childrens Research Institute and the University of Melbourne have identified a new way to accurately test for peanut allergy.

21 Mar 2012

DIAN-TTU to receive $4.2M Alzheimer's Association research grant

The Alzheimer's Association announced today the awarding of its largest ever research grant – nearly $4.2 million dollars over four years – to the Dominantly Inherited Alzheimer's Network–Therapeutic Trials Unit (DIAN-TTU), based at Washington University School of Medicine in St. Louis, to enable the program to move forward more quickly with innovative drug and biomarker trials in people with genetically-based, young-onset Alzheimer's disease.

21 Mar 2012

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Washington University School of Medicine in St. Louis has received nearly $4.2 million from the Alzheimer's Association to accelerate the launch of the first clinical trials to prevent the symptoms of Alzheimer's disease.

21 Mar 2012

FKBP52 may prevent hyperphosphorylation of pathogenic Tau protein

New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer's drugs and for detecting the disease before the onset of clinical symptoms.

21 Mar 2012

Factors that increase the possibility of having migraines

A migraine is the most common type of headache that propels patients to seek care from their doctors. Roughly 30 million Americans suffer from migraine headaches, with women affected almost three times more often than men, according to statistics from the National Headache Foundation in Chicago.

21 Mar 2012

OSU, NCKU sign MOU to improve clinical research on pancreatic cancer

National Cheng Kung University (NCKU) in Tainan, southern Taiwan, signed a memorandum of understanding (MOU) with the Ohio State University (OSU) College of Pharmacy on March 20 at the NCKU College of Medicine as part of its effort to enhance its international academic cooperation and most importantly to improve the clinical research on pancreatic cancer.

21 Mar 2012

New perspective on why the immune system makes us worse while trying to make us well

A new article in The Quarterly Review of Biology helps explain why the immune system often makes us worse while trying to make us well.

21 Mar 2012

Common pain relievers could cause hypertension

Diseases such as kidney failure and endocrine tumors are among the suspects causing high blood pressure - but could the common pain relievers in your medicine cabinet be the culprit? According to Prof. Ehud Grossman of Tel Aviv University's Sackler Faculty of Medicine and the Sheba Medical Center, many common over-the-counter and prescription medications are underlying causes of hypertension, which is a major risk factor for stroke, heart attack, and aneurisms.

21 Mar 2012

Two new studies strongly support link between insulin resistance and Alzheimer's

An emerging body of research suggests that Alzheimer's disease may be linked to insulin resistance, constituting a third type of diabetes. This model is based on several observations including an increased risk of developing Alzheimer's disease for diabetic patients, and reduced insulin levels in the brain tissue of Alzheimer's disease patients. Though intriguing, the existing evidence does not reveal if defective insulin signaling is causative of Alzheimer's or how insulin resistance impacts cognitive function.

21 Mar 2012

Enrollment complete in HAL Allergy PURETHAL Mites Phase II trial for allergic rhinitis/rhinoconjunctivitis

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.

21 Mar 2012

Systagenix announces U.S. launch of EPIFIX amniotic membrane allograft

Systagenix, announced today that it will launch EPIFIX in the United States in March as part of a global distribution agreement reached with MiMedx Group, Inc.

21 Mar 2012

Curcumin can help prevent clumping of proteins in Parkinson's

Curcumin, a compound found in the spice turmeric, is proving effective at preventing clumping of a protein involved in Parkinson's disease, says a Michigan State University researcher.

21 Mar 2012

New drug makes chemotherapy more effective in treating acute myeloid leukemia

Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

21 Mar 2012

Study tests new method of sound simulation for treating tinnitus

A new clinical trial is to test whether a pocket-sized device that uses sound simulation to reboot faulty 'wiring' in the brain could cure people with the debilitating hearing disorder tinnitus.

21 Mar 2012

NCCN issues first ever clinical practice guidelines for ALL

The National Comprehensive Cancer Network has issued its first ever NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia.

21 Mar 2012

Meda's Astepro receives registration approval in Europe

Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.

21 Mar 2012

Cardium commences Generx Phase 3 registration study in myocardial ischemia

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.

21 Mar 2012

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

Delcath receives first commercial order for CHEMOSAT system from IEO

Delcath Systems, Inc. announced today that it has received the first commercial order for the Company's Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe.

20 Mar 2012